Singapore

“Zyfas Medical v. Millennium Pharmaceuticals”

Decision of the Supreme Court of Singapore
27 August 2020 – Case No. [2020] SGCA 84

Zyfas Medical Co v. Millenium Pharmaceuticals, Inc;

Health Products (Therapeutic Products) Regulations
2016 (S 329/2016), reg 23(2)

© Max Planck Institute for Innovation and Competition, Munich 2021

Keywords Process patents · Therapeutic product · Application for registration · Generic drug · Disclosure of existing patents in patent registration application · Application for registration with false, misleading or omitted information

1. **Process patents must be declared in an application for registration of a therapeutic product pursuant to reg 23(2) of the Health Products (Therapeutic Products) Regulations 2016 (S 329/2016).**

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.